Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Precision medicine

Diagnostics

The Evolution of Epigenetic Biomarkers

| Niamh Buckley, Laura Feeney, James Beirne, and Paul Mullan

Markers such as DNA methylation, analyzed by liquid biopsy, may improve on ovarian cancer testing options like gold standard CA125

Inside the Lab

People Power and Machine Learning

| Geoff Twist

A collaboration between industry, academia, and the clinic could lead to more efficient, more personalized cancer diagnosis and treatment

Diagnostics

Sensing the Tiniest Change

| Menno Prins

New biomarker sensing technology can detect miniscule concentrations of molecules in the blood to assist with patient monitoring

Diagnostics

Thinking Outside the (Genome) Box

| Jason Mellad

Epigenetics may combine with liquid biopsy to offer an effective way of detecting early-stage cancers and recurrences

Inside the Lab

Biochip Breakthrough

| Luke Turner

With antimicrobial resistance an ever-increasing threat to modern medicine, a new breakthrough may rapidly identify drug-resistant microbe strains to ensure effective treatment

Inside the Lab

One Drop at a Time

| Alexander Dobrovic and Cloud Paweletz

When seeking the greatest benefit from liquid biopsy, droplet digital PCR can help by offering speed, sensitivity, and absolute quantitation

Outside the Lab

The “We” in Team

| Judith Hugh

What exactly is a multidisciplinary team – and what is the pathologist’s role in it?

Inside the Lab

From Dream to Deployment

| Sponsored by Leica

Leeds Teaching Hospitals NHS Trust and Leica Biosystems have formed a unique partnership to make a 100% digital pathology service a reality

Inside the Lab

Leading the Pack

| Marisa Saint Martin

Pathologists hold the key to diagnostic management teams – and diagnostic management teams have a lot to contribute to patient care

Outside the Lab

Pre-Empting Relapse

| Luke Turner

A new DNA test that can detect treatment-resistant mutations could prove crucial for patients with acute myeloid leukemia, providing an early indication that targeted therapeutic intervention is needed


Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register